Business Standard

India's Covid vaccine hope rolls over to 2021; panel to meet again on Jan 1

Sources close to the development said the expert committee sought more information from Serum Institute regarding the Oxford-AstraZeneca vaccine

vaccine, pharma, coronavirus, medicine, drugs, medical research, covid, lab
Premium

American pharma giant Pfizer, which already has approval in the UK and the US for Covid vaccine in partnership with German major BioNTech, has asked Indian authorities for more time to present its data

Ruchika ChitravanshiSohini Das
Soon after the UK drug regulator approved the Oxford-AstraZeneca vaccine on Wednesday, Indian authorities got into action to consider the applications from key players like Serum Institute of India and Bharat Biotech for emergency use authorisation. Serum Institute is in a tie-up with Oxford-AstraZeneca to manufacture vaccine against Covid-19.

However, following hours of data analysis, the Subject Expert Committee in the Central Drugs Standard Control Organisation (CDSCO) decided to meet again on January 1 for further analysis of the additional information supplied by Serum Institute and Bharat Biotech. A statement issued by the Union Health Ministry confirmed that a meeting of

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in